Senior leader in discovery and development of novel therapeutic drugs accessing the GI tract.
Dr. Caroline Kurtz joined Synlogic in October 2016 and is responsible for all aspects of nonclinical development for Synlogic’s therapeutic programs. Previously, Caroline was vice president and GC-C platform lead at Ironwood Pharmaceuticals, where she drove the development of linaclotide (LINZESS®) from pre-IND through NDA approval and life-cycle management. In this role, she managed the linaclotide development collaborations with U.S. partner Forest (now Allergan), European partner Almirall and Japanese partner Astellas. Through the study of linaclotide’s pharmacology, her team identified a novel mechanism for the relief of visceral pain mediated by the release of cGMP from intestinal epithelial cells. She also served as the portfolio lead for the discovery and development of new GC-C agonists, including identification of two additional clinical candidates.
Visit website: https://www.synlogictx.com/our-people/leadership/
See also: Synlogic - Company designing Synthetic Biotic medicines.
Caroline Kurtz News
New type of medicine made from living bacteria
Guardian - 16-Jan-2019
Can be used to add or remove products from the bodyRead more...